ACRX

Company Update (ACRX): AcelRx Pharmaceuticals Inc Announces Anticipated 2016 Milestones

AcelRx Pharmaceuticals Inc (NASDAQ:ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute pain, announced …

Corey Williams — January 10, 2016, 7:10 AM EDT

Company Update (NASDAQ:ACRX): AcelRx Pharmaceuticals Inc Completes Protocol Review with FDA and Plans to Initiate Phase 3 Open-Label Study or Zalviso

AcelRx Pharmaceuticals Inc (NASDAQ:ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute pain, today …

Corey Williams — January 8, 2016, 7:10 AM EDT

Company Update (NASDAQ:ACRX): AcelRx Pharmaceuticals Inc Receives Notice of Eligibility for Centralized Review of ARX-04 from European Medicines Agency

AcelRx Pharmaceuticals Inc (NASDAQ:ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the intended treatment of acute …

Corey Williams — December 23, 2015, 7:22 AM EDT

Stock Update (NASDAQ:ACRX): AcelRx Pharmaceuticals Inc Conducts Pre-NDA Meeting with U.S. Food and Drug Administration for ARX-04

AcelRx Pharmaceuticals Inc (NASDAQ:ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies designed for the treatment of acute pain, …

Corey Williams — December 14, 2015, 7:22 AM EDT

Stock Update (NASDAQ:ACRX): AcelRx Pharmaceuticals Inc Announces Sublingual Sufentanil Data Presentation at the American Society of Regional Anesthesia and Pain Medicine Meeting

AcelRx Pharmaceuticals Inc (NASDAQ:ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute pain, announced …

Corey Williams — November 19, 2015, 7:29 AM EDT

Stock Update (NASDAQ:ACRX): AcelRx Pharmaceuticals Inc Presents Data from Phase 3 Clinical Trials Evaluating the Safety and Efficacy of Zalviso in Obese Surgical Patients

AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute pain, …

Corey Williams — November 4, 2015, 8:05 AM EDT

AcelRx Pharmaceuticals Inc (ACRX) Provides Business Update and Reports Third Quarter and Nine Months 2015 Financial Results

AcelRx Pharmaceuticals Inc (NASDAQ:ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute pain, today …

Corey Williams — October 29, 2015, 4:17 PM EDT

Company Update (NASDAQ:ACRX): AcelRx Pharmaceuticals Inc Announces Presentation Of Phase 3 Data From ARX-04 Sufentanil Sublingual 30 mcg Program At The ASA Meeting

AcelRx Pharmaceuticals Inc (NASDAQ:ACRX) announced that a presentation will be made at the 2015 Annual Meeting of the American Society of Anesthesiologists (Anesthesiology 2015) …

Corey Williams — October 23, 2015, 8:01 AM EDT

Stock Update (NASDAQ:ACRX): AcelRx Pharmaceuticals Inc Announces Presentation Of Phase 3 Sufentanil Sublingual 30mcg Tablet Data At The European Society Of Emergency Medicine Meeting

AcelRx Pharmaceuticals Inc (NASDAQ:ACRX) announced that a presentation will be made at the annual European Society of Emergency Medicine (EuSEM) meeting to be held …

Corey Williams — October 9, 2015, 8:34 AM EDT

Cowen Weighs In On AcelRx Pharmaceuticals Inc (ACRX) Following Regulatory Update On Zalviso

Cowen’s healthcare analyst Boris Peaker weighed in today with a few insights on AcelRx Pharmaceuticals Inc (NASDAQ:ACRX), after the company provided a regulatory update on Zalviso, which …

Jason Cohen — October 8, 2015, 2:43 PM EDT

« 1 … 3 4 5 6 7 … 9 »

ACRX

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts